FDA approves transformative therapy for sick children from UCLA

On 2026-04-03, the US Food and Drug Administration approved the first gene therapy for severe leukocyte adhesion deficiency-I, a rare and often fatal immune disorder. The therapy, developed by Rocket Pharmaceuticals and reported through UCLA coverage, uses a patient’s own stem cells to restore immune function and reduce life-threatening infections.